Teva’s Christine Baeder Elected as Chair of the Association for Accessible Medicines Board of Directors

Christine Baeder, Teva Pharmaceuticals Chief Operating Officer for U.S. Generics and Biosimilars, was elected Chair of the Association for Accessible Medicines (AAM) Board of Directors during the organization’s Access! 2023 Annual Meeting in Orlando.

Christine has a deep understanding of the value that generic, complex generic and biosimilar medicines provide to patients. Having been at Teva for the past 12 years, she has been an integral part of our commitment to making safe, quality medications accessible and affordable.

“The generics and biosimilars industry is an exemplar of the value that can be delivered to Americans by manufacturers, policy makers, and regulators working together. However, the industry is at a crossroads and faces real threats to its survival. No other sector helps patients afford their health care as much as generic, complex generic and biosimilar medicines, which are needed not only to create access but to free up resources to enable new and novel therapies.” said Christine. “I am humbled that my peers have chosen me to lead at this critical time and determined to be the most forceful and effective advocate possible.”

As Chair, Christine will lead AAM in addressing its advocacy priorities: oppose misguided price setting legislation; accelerate access; and challenge practices from any industry actors that disadvantage generics and biosimilars.

We congratulate Christine on this appointment and look forward to seeing all she will accomplish as Chair of AAM!

Find out more

• Learn more about Christine and other key Teva Generics leaders in a video captured by AAM at our Parsippany, NJ headquarters as part of their ‘Generics Are the Solution’ tour.